Table 4. Association of 2-year decrease in total cholesterol with subsequent endpoint risk by GFR group in study population, unadjusted.
| GFR at baseline | Hazard ratio of 2-year decrease in total cholesterol, per 10 mg/dl cholesterol | ||
|---|---|---|---|
| HR | 95% C.I. | p-value for interaction (change in cholesterol × GFR group) | |
| Mortality | |||
| Total | 1.00 | (0.97 – 1.02) | 0.13 |
| 60+ | 0.98 | (0.95 – 1.01) | |
| < 60 | 1.02 | (0.97 – 1.08) | |
| CHD Events | |||
| Total | 0.95 | (0.92 – 0.98)* | 0.13 |
| 60+ | 0.94 | (0.90 – 0.97)* | |
| < 60 | 0.99 | (0.93 – 1.06) | |
| Combined CVD | |||
| Total | 1.00 | (0.98 – 1.02) | 0.41 |
| 60+ | 0.99 | (0.97 – 1.01) | |
| < 60 | 1.01 | (0.97 – 1.06) | |
*p < 0.05. CHD = coronary heart disease; CI = confidence interval; CVD = cardiovascular disease; GFR = glomerular filtration rate; HR = hazard ratio.